Suzana Kahn

Suzana has 14 years of experience in immuno-oncology research and preclinical drug discovery and development. At Pheast, Suzana manages research initiatives studying immuno-oncology therapeutics. Prior to joining Pheast, Suzana was a senior scientist at Genentech, where she oversaw development, implementation, and execution of clinical biomarker strategies for compounds in the clinical stage. Prior to Genentech, Suzana was at Bristol Myers Squibb, where she led immuno-oncology programs focused on tumor-associated myeloid cells. She completed her postdoctoral training in the laboratory of Dr. Irving Weissman at Stanford University. Suzana received a Ph.D. in cancer biology from Sorbonne University in France and B.S. in biomedical sciences from the Federal University of Rio de Janeiro, Brazil.